No Instant Solution for Rising Health Insurance Expenses: These Accounts May Provide Assistance.
- Rising Insurance Premiums: Insurance premiums are expected to increase significantly next year, affecting millions of Americans.
- Increased Interest in Health Savings Accounts: As a response to rising costs, more Americans may consider utilizing health savings accounts (HSAs) for managing healthcare expenses.
Trade with 70% Backtested Accuracy
Analyst Views on VTI
About the author


Stock Performance: Booking Holdings (BKNG) shares have dropped over 8%, reaching their lowest levels since September 2024, despite better-than-expected fourth-quarter results, due to concerns about potential AI disruption.
Revenue Growth: The company reported a 16% increase in fourth-quarter revenue to $6.3 billion, surpassing Street estimates, and projected low double-digit revenue growth for fiscal 2026.
Stock Split Announcement: Booking's board approved a 25-for-1 stock split, effective April 2, which will adjust trading on a split-adjusted basis starting April 6.
Analyst Ratings: Analysts have reduced price targets for Booking, with Cantor Fitzgerald lowering it to $4,495 and Barclays to $5,500, while maintaining neutral or overweight ratings, reflecting concerns about AI developments impacting stock valuation.

Michael Saylor's Insights on Bitcoin: Strategy Inc. co-founder Michael Saylor discussed Bitcoin's volatility, stating that while it can be seen as a bug, it is also a feature that makes it a superior form of digital capital compared to traditional assets like gold and real estate.
Performance Comparison: Saylor emphasized that Bitcoin has outperformed traditional assets by two to four times, highlighting its potential as a new financial instrument he refers to as "digital credit."
Market Trends: On the day of the interview, Strategy's shares fell nearly 5%, reflecting a neutral sentiment among retail investors regarding the company.
Current Bitcoin Prices: At the time of writing, Bitcoin prices hovered around $68,600, showing a slight decline of 0.7% over the previous 24 hours.

Internal Review Findings: Capital Watch revealed that an internal review found insufficient independent verification processes related to the Court of Bordeaux's judgment, leading to erroneous associations with Hao Tang.
Retraction of Allegations: Capital Watch has formally retracted its claims of financial crimes against Hao Tang and other individuals, acknowledging inaccuracies in earlier reports regarding direct connections to alleged illicit activities.
Continued Analysis: Despite the retraction, Capital Watch maintains its stance on the complexity of AppLovin's financial structure and will continue to independently analyze public market data related to the firm.
Market Reaction: Following the retraction, shares of AppLovin experienced volatility, initially dropping but later gaining over 21% in the past year, reflecting mixed sentiment among investors.
Stock Split Announcement: Atossa Therapeutics has combined its 15 shares of common stock into one new share following a reverse stock split approved by its Board of Directors, effective February 2, 2026.
FDA Orphan Drug Designation: The FDA granted Orphan Drug Designation to Atossa's drug, Z-endoxifen, for the treatment of Duchenne muscular dystrophy, which is a severe genetic disorder primarily affecting boys.
Stock Performance: Following the stock split, Atossa's shares fell by 32% on the first day of trading, reflecting ongoing concerns among investors about potential dilution and the company's overall performance.
Financial Position: As of the end of September, Atossa reported cash and cash equivalents totaling $51.8 million, despite experiencing a 54% decline in stock value over the past year.

Tesla's Subscription Model: Tesla is transitioning its full self-driving (FSD) technology to a subscription model, which has raised concerns among analysts regarding its valuation as an appreciating asset.
Pricing Strategy: The pricing decision for the FSD subscription is seen as a crucial step towards standardizing software offerings for vehicles over the next five years, despite the current small customer base.
Market Reaction: Following the announcement, Tesla's stock experienced a decline, with analysts expressing skepticism about the technology's current capabilities and its impact on future valuations.
Future Outlook: Elon Musk indicated that the subscription service would begin on February 14, and there are calls for Tesla to reduce subscription costs to attract more customers and increase adoption rates.

Tesla's Q4 Deliveries: In the fourth quarter of 2025, Tesla reported 418,227 vehicle deliveries, reflecting a 16% decline from the same quarter in 2024 and falling short of Wall Street expectations.
Earnings Expectations: Analysts anticipate Tesla will report Q4 revenue of $24.80 billion, below the $25.71 billion reported in Q4 2024, with adjusted earnings per share expected to be $0.44, down from $0.73 in the previous year.
Concerns Over EV Sales: Gary Black from Future Fund LLC expressed concerns about Tesla's declining electric vehicle sales impacting the company's share price, noting that EVs constitute over 70% of Tesla's profits.
Stock Market Sentiment: Despite recent challenges, Tesla's stock has gained 11% over the past year, with retail sentiment remaining bearish, although trading volumes have normalized after a period of high activity.





